Related Experiment Video
Updated: Jul 8, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Third-line Treatment for Metastatic Triple-negative Breast Cancer: A Systematic Review and Network Meta-analysis
Mingqiang Shi1, Zhoujuan Li, Tianzhuo Wang
1Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University and Affiliated Cancer Hospital of Qinghai University, Xining, Qinghai, China.
Objective:
Metastatic triple-negative breast cancer (mTNBC) is an invasive histologic subtype with a poor prognosis and rapid progression. Currently, there is no standard therapy for the third-line treatment of mTNBC. In this study, we conducted a network meta-analysis to compare regimens and determine treatment outcomes.
Methods:
We performed a systematic search of PubMed, EMBASE, the Cochrane Central Register of Controlled Bases, and the minutes of major conferences. Progression-free survival, overall survival, and objective response rate were analyzed through network meta-analysis using the R software (R Core Team). The efficacy of the treatment regimens was compared using hazard ratios, odds ratios, and 95% CIs.
Results:
We evaluated 15 randomized controlled trials involving 6,010 patients. Compared with the physician's choice treatment, sacituzumab govitecan showed significant advantages in progression-free survival and overall survival, with hazard ratio values of 0.41 (95% CI: 0.32-0.52) and 0.48 (95% CI, 0.39-0.60). In terms of objective response rate, sacituzumab govitecan is the best-performing therapy (odds ratio: 10.82; 95% CI: 5.58-20.97). Adverse events among grades 3 to 5 adverse reactions, the incidence of neutropenia and leukopenia in each regimen was higher, whereas the incidence of fever, headache, hypertension, and rash was lower.
Conclusion:
Compared with the treatment of the physician's choice, sacituzumab govitecan appears more efficacious and is the preferred third-line treatment for mTNBC.
Insights
Sacituzumab govitecan is the preferred third-line treatment for metastatic triple-negative breast cancer (mTNBC), demonstrating superior progression-free survival and overall survival compared to physician's choice. This therapy also shows the best objective response rate in mTNBC patients.
Area of Science:
- Oncology
- Clinical Trials
- Pharmacology
Background:
- Metastatic triple-negative breast cancer (mTNBC) presents a significant clinical challenge due to its aggressive nature and lack of established third-line treatment options.
- Current therapeutic strategies for mTNBC often yield suboptimal outcomes, highlighting the need for more effective interventions.
Conclusions:
- Sacituzumab govitecan is a highly efficacious third-line treatment option for mTNBC.
- This therapy offers significant advantages in survival outcomes and response rates compared to physician's choice, establishing it as a preferred treatment regimen.
